Skip to main content
Terug
Watch Compare

Protalix BioTherapeutics, Inc.

Datakwaliteit: 100%
PLX
NYSE Manufacturing Chemicals
€ 2,29
▲ € 0,04 (1,56%)
Marktkapitalisatie: 184,11 M
Prijs
€ 2,29
Marktkapitalisatie
184,11 M
Dagbereik
€ 2,19 — € 2,29
52-Weeksbereik
€ 1,32 — € 3,19
Volume
671.399
Openen € 2,25
50D / 200D Gem.
€ 2,61
12,30% below
50D / 200D Gem.
€ 2,02
12,96% above

Quick Summary

Belangrijkste Punten

Revenue grew 8,29% annually over 5 years — modest growth
Earnings declined -325,24% over the past year
Negative free cash flow of -13,63 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9,52%
Capital efficient — spends only 3,11% of revenue on capex

Groei

Revenue Growth (5Y)
8,29%
Onder sectorgemiddelde (9,35%)
Revenue (1Y)-1,23%
Earnings (1Y)-325,24%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-12,85%
Boven sectorgemiddelde (-51,02%)
ROIC-7,58%
Net Margin-12,52%
Op. Margin-10,43%

Veiligheid

Debt / Equity
N/A
Current Ratio3,03
Interest CoverageN/A

Waardering

PE (TTM)
-27,88
Onder sectorgemiddelde (-1,98)
P/B Ratio3,48
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -27,9 -2,0
P/B 3,5 5,1
ROE % -12,9 -51,0
Net Margin % -12,5 -150,2
Rev Growth 5Y % 8,3 9,3
D/E — 0,3

ETFs Holding This Stock

DEEF logo DEEF Xtrackers FTSE Developed ex US Multifactor ETF
0,06% weight
DBEZ logo DBEZ Xtrackers MSCI Eurozone Hedged Equity ETF
0,02% weight
NTSI logo NTSI WisdomTree International Efficient Core Fund
0,01% weight
GTPE logo GTPE Goldman Sachs MSCI World Private Equity Return Tracker ETF
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -1,23% Revenue Growth (3Y) -10,26%
Earnings Growth (1Y) -325,24% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,29% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 52,74 M Net Income (TTM) -6,60 M
ROE -12,85% ROA -8,22%
Gross Margin N/A Operating Margin -10,43%
Net Margin -12,52% Free Cash Flow (TTM) -13,63 M
ROIC -7,58% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,03
Interest Coverage N/A Asset Turnover 0,66
Working Capital 44,56 M Tangible Book Value 52,91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -27,88 Forward P/E N/A
P/B Ratio 3,48 P/S Ratio 3,49
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,40%
Market Cap 184,11 M Enterprise Value 170,46 M
Per Share
EPS (Diluted TTM) -0,08 Revenue / Share 0,65
FCF / Share -0,17 OCF / Share -0,15
EPS CAGR (1Y) -300,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,11% FCF Conversion 206,41%
SBC-Adj. FCF -15,82 M Growth Momentum -9,52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 52,74 M 53,40 M 65,49 M 47,64 M 38,35 M
Net Income -6,60 M 2,93 M 8,31 M -14,93 M -27,58 M
EPS (Diluted) -0,08 0,04 0,09 -0,31 -0,62
Gross Profit — — — — —
Operating Income -5,50 M 3,92 M 10,46 M -13,01 M -20,46 M
EBITDA — — — — —
R&D Expenses 19,57 M 12,97 M 17,09 M 29,35 M 29,73 M
SG&A Expenses 11,68 M 12,19 M 14,96 M 11,71 M 12,73 M
D&A — — — — —
Interest Expense — — — — —
Income Tax 996.000,0 1,22 M 254.000,0 530.000,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 82,35 M 73,42 M 84,43 M 55,79 M 73,67 M
Total Liabilities 34,12 M 30,21 M 50,87 M 66,43 M 79,70 M
Shareholders' Equity 48,23 M 43,21 M 33,57 M -10,64 M -6,04 M
Total Debt — — — — —
Cash & Equivalents 14,68 M 19,76 M 23,63 M 17,11 M 38,99 M
Current Assets 66,67 M 60,08 M 69,93 M 44,88 M 61,67 M
Current Liabilities 26,52 M 25,62 M 45,53 M 32,43 M 33,18 M